Extensive safety testing and manufacturing improvements have now made it possible to bring the drug back to the US market.
Findings from the phase 3 MATTERHORN trial supported the FDA approval of perioperative durvalumab for resectable gastric and GEJ cancers.
HealthDay News — Eli Lilly reached a major milestone Friday, becoming the first healthcare company in the world to hit a $1 trillion market value. The drug company briefly crossed the trillion-dollar ...
Childhood exposure linked to modestly better cognition in secondary school, but no significant difference seen at age ~60 years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback